SOURCE: Addison-Davis Diagnostics, Inc.

October 03, 2005 12:26 ET

Addison-Davis Diagnostics Receives Second Purchase Order From Miami-Dade County for "Drug-Stop"

WESTLAKE VILLAGE, CA -- (MARKET WIRE) -- October 3, 2005 -- Addison-Davis Diagnostics, Inc. (OTC BB: ADDI) is pleased to announce that they have already received their second purchase order from Miami-Dade County, FL. This time the purchase order is for the Internal Affairs Department. In August, Addison-Davis was awarded a bid to exclusively supply "Drug Stop," the Addison-Davis on site drug screening test, to the Turner Guilford Knight Correctional Center.

The Turner Guilford Knight Correctional Center has 1300 beds for male and female inmates of various levels of custody and has an active drug-testing program. "We are excited that we are expanding our relationship to the other departments within the county. To have our second purchase order within 2 months says a lot," stated Edward Withrow, CEO of Addison-Davis Diagnostics, Inc.

"Drug Stop" has already received 510K and Over-The-Counter Clearance from the FDA. "Drug Stop" is a self-regulating urine specimen test using the latest on-site drug screening technology. The process used by the "Drug Stop" product is one of the easiest to use on-site drug screening tests. Addison-Davis is targeting the $2.2 Billion substance abuse market with "Drug Stop."

About Addison-Davis

Addison-Davis Diagnostics, Inc. is responding to industry demands by supplying quick response diagnostic tests that are user friendly, produce fast simple results and are less costly, less problematic and less time consuming. Addison-Davis is currently focused on bringing fast and reliable "Point-of-care" Diagnostic Testing through the use of its patented technology to Healthcare Professionals, Hospitals, certain branches of the Government and the Workplace environment for drugs-of-abuse and medical conditions and diseases.

For more information please visit our website or contact Matt Maguire at 1-866 THE APPL(E)

Safe Harbor

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approvals for anticipated actions.

Contact Information